| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
SVP, Clinical Development | VP, Clinical Trial Operations
1 company
Yu Yong is a SVP, Clinical Development at GENELUX Corp. Recent SEC Form 4 filings include 0 buys and 11 sells.
Estimated insider holdings value: $423K based on current market prices.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Oct 10, 2023 | GNLX Genelux Corp | VP, Clinical Trial Operations | Sale+OE | 5,200 | $22.01 | $114,461.92 | -2.4% | -36.6% | -88.1% | |
| Sep 26, 2023 | GNLX Genelux Corp | VP, Clinical Trial Operations | Sale+OE | 5,200 | $23.56 | $122,527.86 | -1.6% | -33.1% | -91.2% | |
| Sep 20, 2023 | GNLX Genelux Corp | VP, Clinical Trial Operations | Sale+OE | 6,000 | $27.96 | $167,785.80 | -5.4% | -52.7% | -91.8% | |
| Sep 15, 2023 | GNLX Genelux Corp | VP, Clinical Trial Operations | Sale+OE | 10,400 | $21.89 | $227,630.23 | -4.6% | -34.5% | -89.2% | |
| Sep 13, 2023 | GNLX Genelux Corp | VP, Clinical Trial Operations | Sell | 29,800 | $21.14 | $629,927.30 | -21.9% | -40.2% | -87.4% | |
| Aug 30, 2023 | GNLX Genelux Corp | VP, Clinical Trial Operations | Sell | 19,800 | $24.70 | $489,060.00 | -12.7% | -58.0% | -92.0% | |
| Aug 18, 2023 | GNLX Genelux Corp | VP, Clinical Trial Operations | Sell | 3,265 | $23.73 | $77,478.45 | -2.1% | -45.3% | -91.6% |